Thompson Street Capital Partners Portfolio Company Bioreclamation Acquires In Vitro Technologies
ST. LOUIS (June 28, 2013) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company Bioreclamation has acquired Baltimore-based In Vitro Technologies, provider of hepatocyte cells and other in vitro research tools to support the screening of drug compounds in early-stage drug discovery and development. Terms of the transaction were not disclosed.
In Vitro Technologies (IVT) provides specialized in vitro products for the study of metabolism, drug-to-drug interactions and toxicity in drug discovery and development. Its cryoplateable hepatocytes and other ADMET research tools are shipped worldwide and fresh plated hepatocytes throughout North America and Western Europe. The company also offers microsomes as well as custom cell products such as specific tissue or organ material, a particular species, specific characterization or activity targets or a unique product format.
Said Bob Dunn, Managing Director of TSCP, “IVT has the unique capability to offer an unmatched range of biologics and differentiated in-vitro research tools to its customers.” Added Mr. Dunn, “This addition to the Bioreclamation family greatly increases our capabilities to serve researchers operating throughout the world. We’re looking forward to helping the company realize its growth goals – both organically and via additional complementary acquisitions.”